{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:35:56Z","timestamp":1793010956800,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Spine"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.bas.2026.106047","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:19:56Z","timestamp":1775899196000},"page":"106047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Relevance of a complete re-resection of contrast enhancing tumor in MGMT promotor non-methylated versus methylated recurrent glioblastomas"],"prefix":"10.1016","volume":"6","author":[{"given":"Dragan","family":"Jankovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9274-0350","authenticated-orcid":false,"given":"Santhosh G.","family":"Thavarajasingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0172-679X","authenticated-orcid":false,"given":"Daniel","family":"Scurtu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9329-1550","authenticated-orcid":false,"given":"Alice","family":"Dauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9001-8006","authenticated-orcid":false,"given":"Harald","family":"Krenzlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Kalasauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-0178","authenticated-orcid":false,"given":"Andreas","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9182-8377","authenticated-orcid":false,"given":"Clemens","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5858-2369","authenticated-orcid":false,"given":"Petra","family":"Leukel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Stockinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Keric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-7543","authenticated-orcid":false,"given":"Florian","family":"Ringel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bas.2026.106047_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13060999","article-title":"MGMT promoter methylation: prognostication beyond treatment response","volume":"13","author":"Ashkan","year":"2023","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.bas.2026.106047_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-023-04348-w","article-title":"Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis","volume":"164","author":"Ballo","year":"2023","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib3","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/cncr.21539","article-title":"A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999","volume":"104","author":"Chakrabarti","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bas.2026.106047_bib4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3174\/ajnr.A7004","article-title":"MGMT promoter methylation status in initial and recurrent glioblastoma: correlation Study with DWI and DSC PWI features","volume":"42","author":"Choi","year":"2021","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.bas.2026.106047_bib5","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/neuros\/nyab345","article-title":"Is there a role for surgical resection of multifocal glioblastoma? A retrospective analysis of 100 patients","volume":"89","author":"Friso","year":"2021","journal-title":"Neurosurgery"},{"key":"10.1016\/j.bas.2026.106047_bib6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/neuonc\/not236","article-title":"Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials","volume":"16","author":"Han","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bas.2026.106047_bib8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bas.2026.106047_bib9","series-title":"Glioblastoma Multiforme","author":"Kanderi","year":"2024"},{"key":"10.1016\/j.bas.2026.106047_bib10","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib11","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/neuonc\/noad074","article-title":"Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11060-024-04810-3","article-title":"Multimodal treatment of glioblastoma with multiple lesions - a multi-center retrospective analysis","volume":"170","author":"Krenzlin","year":"2024","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11060-018-03059-x","article-title":"Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO)","volume":"142","author":"Navarria","year":"2019","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3171\/2013.12.JNS13184","article-title":"An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity","volume":"120","author":"Oppenlander","year":"2014","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.bas.2026.106047_bib18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: a \"state of the science\" review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/02688697.2018.1501465","article-title":"The enigma of multicentric glioblastoma: physiopathogenic hypothesis and discussion about two cases","volume":"32","author":"Picart","year":"2018","journal-title":"Br. J. Neurosurg."},{"key":"10.1016\/j.bas.2026.106047_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/neuonc\/nov145","article-title":"Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection","volume":"18","author":"Ringel","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nop020","article-title":"MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma","volume":"12","author":"Rivera","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bas.2026.106047_bib23","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bas.2026.106047_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10555-022-10051-5","article-title":"The multifaceted mechanisms of malignant glioblastoma progression and clinical implications","volume":"41","author":"Sun","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bas.2026.106047_bib25","series-title":"Epidemiology and Outcome of Glioblastoma","first-page":"143","author":"Tamimi","year":"2017"},{"key":"10.1016\/j.bas.2026.106047_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11910-014-0507-z","article-title":"Treatment considerations for MGMT-unmethylated glioblastoma","volume":"15","author":"Taylor","year":"2015","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.bas.2026.106047_bib27","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/ijc.33363","article-title":"MGMT promoter methylation analysis for allocating combined CCNU\/TMZ chemotherapy: lessons learned from the CeTeG\/NOA-09 trial","volume":"148","author":"Tzaridis","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bas.2026.106047_bib28","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102029","article-title":"How did lomustine become standard of care in recurrent glioblastoma?","volume":"87","author":"Weller","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bas.2026.106047_bib30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bas.2026.106047_bib31","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and Bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Brain and Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772529426001232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772529426001232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T10:16:11Z","timestamp":1793009771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772529426001232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":31,"alternative-id":["S2772529426001232"],"URL":"https:\/\/doi.org\/10.1016\/j.bas.2026.106047","relation":{},"ISSN":["2772-5294"],"issn-type":[{"value":"2772-5294","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relevance of a complete re-resection of contrast enhancing tumor in MGMT promotor non-methylated versus methylated recurrent glioblastomas","name":"articletitle","label":"Article Title"},{"value":"Brain and Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bas.2026.106047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of EANS, the European Association of Neurosurgical Societies, EUROSPINE, the Spine Society of Europe.","name":"copyright","label":"Copyright"}],"article-number":"106047"}}